Ractigen Therapeutics
Nantong
About Ractigen Therapeutics
Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $47.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2022)
- Website: ractigen.com
- Phone: (+86) 513-81996959
Industries & Categories
Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ractigen-therapeutics-95185 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.